Validation of Belun Ring Gen3 Deep Learning Algorithms With Subxiphoid Body Sensor

Last updated: July 19, 2024
Sponsor: Belun Technology Company Limited
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sleep Apnea Syndromes

Arrhythmia

Treatment

Belun Cor

Belun Ring

Clinical Study ID

NCT06255613
STUDY20231436
  • Ages 18-80
  • All Genders

Study Summary

Hypothesis: BR's Gen3 DL algorithms, combined with its subxiphoid body sensor, can accurately diagnose OSA, categorize its severity, identify REM OSA and supine OSA, and detect central sleep apnea (CSA).

Primary Objective:

To rigorously evaluate the overall performance of the BR with Gen3 DL Algorithms and Subxiphoid Body Sensor in assessing SDB in individuals referred to the sleep labs with clinical suspicion of sleep apnea and a STOP-Bang score > 3, by comparing to the attended in-lab PSG, the gold standard.

Secondary Objectives:

To determine the accuracy of BR sleep stage parameters using the Gen3 DL algorithms by comparing to the in-lab PSG;

To assess the accuracy of the BR arrhythmia detection algorithm;

To assess the impact of CPAP on HRV (both time- and frequency-domain), delta HR, hypoxic burden, and PWADI during split night studies;

To assess if any of the baseline HRV parameters (both time- and frequency-domain), delta heart rate (referred to as Delta HR), hypoxic burden, and pulse wave amplitude drop index (PWADI) or the change of these parameters may predict CPAP compliance;

To evaluate the minimum duration of quality data necessary for BR to achieve OSA diagnosis;

To examine the performance of OSA screening tools using OSA predictive AI models formulated by National Taiwan University Hospital (NTUH) and Northeast Ohio Medical University (NEOMED).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of signed informed consent form.

  • Clinically assessed and suspicious for OSA with a STOP-Bang score ≥ 3.

Exclusion

Exclusion Criteria:

  • Full night PAP titration study.

  • On home O2, noninvasive ventilator, diaphragmatic pacing, or any form of a nervestimulator.

  • Having atrial fibrillation-flutter, pacemaker/defibrillator, left ventricular assistdevice (LVAD), or status post cardiac transplantation.

  • Recent hospitalization or recent surgery in the past 30 days.

  • Unstable cardiopulmonary status on the night of the study judged to be unsafe forsleep study by the sleep tech and/or the on-call sleep physician.

If a participant did not sleep for at least 4 hours of technically valid sleep based on the Belun Ring method for diagnostic assessments, or a minimum of 3 hours of technically valid sleep during the diagnostic phase of a split-night study, the patient will be excluded from statistical analysis.

Study Design

Total Participants: 79
Treatment Group(s): 2
Primary Treatment: Belun Cor
Phase:
Study Start date:
July 19, 2024
Estimated Completion Date:
September 30, 2027

Connect with a study center

  • UH Geauga Health Center Services

    Chardon, Ohio 44024
    United States

    Active - Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio 44106
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.